Monoclonal Antibody Development

ABS is a state of the art biotechnology company

located in Clay County, Tennessee.  Our main focus is the development of novel monoclonal antibodies highly conserved proteins as well as small molecules, peptides targets and proteins.  Our goal is to provide the best antibodies for our clients in pharmaceutical research companies as well as academia and government.

ABS has a highly dedicated and competent team of scientist solely dedicated to the production of excellent quality monoclonal antibodies.  Our expertise in tissue culture, biochemistry, molecular biology, chemistry, biology and bioengineering ensures that our final product meets the highest standards.  ABS has multiple fully equipped tissue culture rooms solely dedicated for the production of hybridomas, in addition multiple rooms are dedicated to biochemistry, chemistry and molecular biology with state of the art equipments.  Our purification room is second to none other research and development or academic institutions;  housing equipments such as Biacore, HPLC, Nanodrop, and Spectrophotometers.

Our scientific team continues to adapt to new techniques in order to provide the highest quality antibodies.  As the industry of research evolves, ABS will provide a solid portfolio of antibodies and immunological serves at a reasonable price to support the needs of our clients.

Overview (Timeline)

Timeline for delivery of custom monoclonal antibodies that covers a span of 12 months.

Fusion and Screening

Immunized B cells and myeloma cells will be fused and selected via HPRT (HAT selection). HPRT has aminopterin in the medium blocks the de novo pathway. Hence, unfused myeloma cells die, as they cannot produce nucleotides by the de novo or salvage pathway. Unfused B cells die as they have a short lifespan. In this way, only the B cell-myeloma hybrids survive. Fused cells will be plated into semi-solid media allowing for colonies to form then each colony will be screened for functionality. Positive hybridomas will be re-cloned until the cell line is considered stable. Each stable clone will then move on to phase three to get characterized and expanded.

Selection and Expansion

The selection and expansion involve characterizing all cell lines, selecting the most applicable one, and expanding the culture for purification. Characterization includes ranking the cell lines on antibody production, scouted affinity, epitope binning, and antibody isotype. Once the most appropriate cell line is chosen, those cell lines will be adapted to define serum free media and up-scaled for purification.

Purification and Delivery

Antibodies will be purified through affinity chromatography using Protein A or Protein G. The final product will be buffer exchanged into PBS unless stated otherwise. Purified antibodies will go through a final functionality test and concentration analysis. All information regarding each phase will be compiled into a final report which will be delivered with the final product.

Deliverables

Immunized B Cells:
If requested we can deliver cryopreserved immunized B cells to the client for their conformational testing.

Positive Culture Supernatant:
If requested we can send positive culture supernatant to the client for their conformational testing.

Small Scale Purified Product <1mg:
Hybridomas:
Adapted to Serum Free Media.

Monoclonal Antibodies:
We will deliver a desired amount of antibody against the target protein.